Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 25, 2017 06:30 ET | Source: Epizyme, Inc.

Epizyme Announces Date of Third Quarter 2017 Financial Results

CAMBRIDGE, Mass., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will...
September 19, 2017 06:30 ET | Source: Epizyme, Inc.

Epizyme Announces Closing of Public Offering of Common Stock

CAMBRIDGE, Mass., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced the closing of its...
September 14, 2017 06:30 ET | Source: Epizyme, Inc.

Epizyme Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced the pricing of an...
September 13, 2017 16:01 ET | Source: Epizyme, Inc.

Epizyme Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that it intends to...
August 30, 2017 06:30 ET | Source: Epizyme, Inc.

Epizyme to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will...
August 15, 2017 06:30 ET | Source: Epizyme, Inc.

Epizyme Announces Leadership Transition for Finance Organization

CAMBRIDGE, Mass., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced a leadership...
August 04, 2017 06:30 ET | Source: Epizyme, Inc.

Epizyme Reports Second Quarter 2017 Financial Results and Clinical and Business Progress

Key Clinical Milestones Achieved in Studies of Mesothelioma, Epithelioid Sarcoma and Pediatric Solid Tumors Expansion of Collaborations to Accelerate Investigation of Tazemetostat Across Multiple...
August 01, 2017 06:30 ET | Source: Epizyme, Inc.

US Oncology Research and Epizyme Establish Collaboration to Identify Non-Hodgkin Lymphoma Patients with EZH2 Mutations

THE WOODLANDS, Texas and CAMBRIDGE, Mass., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, and US...
July 31, 2017 06:30 ET | Source: Epizyme, Inc.

Epizyme Announces Date of Second Quarter Financial Results and Presentation at Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass., July 31, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will...
July 24, 2017 16:05 ET | Source: Epizyme, Inc.

Epizyme Announces Tazemetostat to be Evaluated in NCI’s Recently Initiated NCI-COG Pediatric MATCH Trial

CAMBRIDGE, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the National...